$RVNC
Revance Therapeutics, Inc. Stock $rvnc

$rvnc Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-K Financial Statement

#000147929019000030 Filed on February 28, 2019

Income Statement

Concept	2019 Q1	2017 Q4	2017 Q3
Revenue	$278.0K	$37.00K	$75.00K
YoY Change	44.04%	-50.67%	0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$12.91M	$11.89M	$9.148M
YoY Change	-5.19%	67.46%	21.94%
% of Gross Profit
Research & Development	$24.00M	$21.00M	$21.64M
YoY Change	7.9%	67.6%	110.21%
% of Gross Profit
Depreciation & Amortization	$628.0K	$370.0K	$380.0K
YoY Change	61.03%	-2.63%	2.7%
% of Gross Profit
Operating Expenses	$36.91M	$32.89M	$30.79M
YoY Change	2.93%	67.55%	73.0%
Operating Profit	-$36.63M		-$30.72M
YoY Change	2.71%		73.31%
Interest Expense	$0.00	$10.00K	$104.0K
YoY Change	-100.0%	-200.0%	-59.38%
% of Operating Profit
Other Income/Expense, Net	-$155.0K	-$140.0K	-$128.0K
YoY Change	-51.41%	7.69%	-7.25%
Pretax Income	-$35.30M	-$35.91M	-$30.65M
YoY Change	0.74%	33.99%	70.47%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$35.30M	-$40.62M	-$30.65M
YoY Change	0.76%	51.54%	70.49%
Net Earnings / Revenue	-12699.28%	-109772.97%	-40868.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$848.6K	-$1.139M	-$1.013M
COMMON SHARES
Basic Shares Outstanding	44.03M shares	30.93M shares	30.82M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q1	2017 Q4	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$271.0M	$282.9M	$153.4M
YoY Change	0.82%	52.51%	-23.8%
Cash & Equivalents	$65.27M	$282.9M	$56.32M
Short-Term Investments	$205.7M	$0.00	$97.10M
Other Short-Term Assets	$6.100M	$444.0K	$2.800M
YoY Change	32.61%	172.39%	-62.16%
Inventory
Prepaid Expenses		$1.823M
Receivables	$0.00	$48.00K
Other Receivables	$0.00
Total Short-Term Assets	$277.1M	$285.2M	$156.3M
YoY Change	1.35%	48.01%	-25.12%
LONG-TERM ASSETS
Property, Plant & Equipment	$15.38M	$9.250M	$11.50M
YoY Change	52.8%	-12.61%	-33.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.146M	$658.0K	$836.0K
YoY Change	338.16%	31.6%	292.49%
Total Long-Term Assets	$47.36M	$10.49M	$12.92M
YoY Change	316.82%	-10.09%	-28.95%
TOTAL ASSETS
Total Short-Term Assets	$277.1M	$285.2M	$156.3M
Total Long-Term Assets	$47.36M	$10.49M	$12.92M
Total Assets	$324.5M	$295.7M	$169.2M
YoY Change	13.94%	44.7%	-25.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.486M	$6.805M	$6.680M
YoY Change	-16.32%	81.27%	132.67%
Accrued Expenses	$13.52M	$12.23M	$12.07M
YoY Change	21.59%	-1.55%	6.75%
Deferred Revenue	$13.05M	$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$1.900M	$2.700M
YoY Change		-45.71%	-18.18%
Total Short-Term Liabilities	$34.07M	$20.90M	$21.48M
YoY Change	48.16%	6.39%	22.61%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$69.30M	$0.00	$0.00
YoY Change	176.1%	-100.0%	-100.0%
Total Long-Term Liabilities	$69.30M	$0.00	$0.00
YoY Change	176.1%	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$34.07M	$20.90M	$21.48M
Total Long-Term Liabilities	$69.30M	$0.00	$0.00
Total Liabilities	$103.4M	$26.85M	$27.13M
YoY Change	114.74%	-1.59%	3.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$720.1M	-$542.2M	-$506.3M
YoY Change	24.76%	28.61%	28.25%
Common Stock	$941.1M	$811.0M	$648.4M
YoY Change	15.6%	35.47%	8.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$221.1M	$268.8M	$142.1M
YoY Change
Total Liabilities & Shareholders Equity	$324.5M	$295.7M	$169.2M
YoY Change	13.94%	44.7%	-25.42%

Cashflow Statement

Concept	2019 Q1	2017 Q4	2017 Q3
OPERATING ACTIVITIES
Net Income	-$35.30M	-$40.62M	-$30.65M
YoY Change	0.76%	51.54%	70.49%
Depreciation, Depletion And Amortization	$628.0K	$370.0K	$380.0K
YoY Change	61.03%	-2.63%	2.7%
Cash From Operating Activities	-$11.41M	-$28.39M	-$21.47M
YoY Change	2.42%	110.76%	49.62%
INVESTING ACTIVITIES
Capital Expenditures	$1.084M	-$490.0K	-$530.0K
YoY Change	1.5%	-5.77%	231.25%
Acquisitions
YoY Change
Other Investing Activities	-$102.4M	$96.79M	$15.00M
YoY Change	-48.63%	-284.96%	-83.87%
Cash From Investing Activities	-$103.4M	$96.30M	$14.47M
YoY Change	-48.36%	-282.25%	-84.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$106.9M	158.7M	9.120M
YoY Change	-4909.54%	-23780.6%	-1481.82%
NET CHANGE
Cash From Operating Activities	-$11.41M	-28.39M	-21.47M
Cash From Investing Activities	-$103.4M	96.30M	14.47M
Cash From Financing Activities	$106.9M	158.7M	9.120M
Net Change In Cash	-$7.987M	226.6M	2.120M
YoY Change	-96.26%	-438.27%	-97.28%
FREE CASH FLOW
Cash From Operating Activities	-$11.41M	-$28.39M	-$21.47M
Capital Expenditures	$1.084M	-$490.0K	-$530.0K
Free Cash Flow	-$12.50M	-$27.90M	-$20.94M
YoY Change	2.34%	115.44%	47.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018	dei	Amendment Flag AmendmentFlag	false
CY2018	dei	Entity Central Index Key EntityCentralIndexKey	0001479290
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2018	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2018Q2	dei	Entity Public Float EntityPublicFloat	1000000000	USD
CY2018	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-12-31
CY2018	dei	Document Type DocumentType	10-K
CY2018	dei	Entity Registrant Name EntityRegistrantName	Revance Therapeutics, Inc.
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Small Business EntitySmallBusiness	false
CY2018	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2018	rvnc	Tax Cutsand Jobs Actof2017 Increase Decreaseto Valuation Allowance TaxCutsandJobsActof2017IncreaseDecreasetoValuationAllowance	-62900000	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36516075	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36975203	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36516075	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36975203	shares
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	5300000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	700000	USD
CY2017Q4	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	0	shares
CY2017Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2017Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2018Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	44028590	shares
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	73256000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	282896000	USD
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	102556000	USD
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	27000000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	48000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5110000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2267000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	207922000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	285211000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14449000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9250000	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	730000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	580000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3247000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	658000	USD
CY2018Q4	us-gaap	Assets Assets	226348000	USD
CY2017Q4	us-gaap	Assets Assets	295699000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8434000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6805000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14948000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12225000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8588000	USD
CY2017Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
CY2018Q4	rvnc	Financing Obligation Current FinancingObligationCurrent	0	USD
CY2017Q4	rvnc	Financing Obligation Current FinancingObligationCurrent	1872000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31970000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20902000	USD
CY2018Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2753000	USD
CY2017Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2613000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	42684000	USD
CY2017Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3319000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3339000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	80726000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	26854000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	37000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	37000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	830368000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	810975000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-684775000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-542167000	USD
CY2016	us-gaap	Asset Impairment Charges AssetImpairmentCharges	9059000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	146363000	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	120686000	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	88515000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-142634000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-120424000	USD
CY2018	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2017	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2927000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	145622000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	268845000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	226348000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	295699000	USD
CY2018	us-gaap	Revenues Revenues	3729000	USD
CY2017	us-gaap	Revenues Revenues	262000	USD
CY2016	us-gaap	Revenues Revenues	300000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	92500000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	80361000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50381000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	53863000	USD
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	37398000	USD
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	29075000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-88215000	USD
CY2018	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	4023000	USD
CY2017	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	1410000	USD
CY2016	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	1170000	USD
CY2018	us-gaap	Interest Expense InterestExpense	44000	USD
CY2017	us-gaap	Interest Expense InterestExpense	457000	USD
CY2016	us-gaap	Interest Expense InterestExpense	1082000	USD
CY2018	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-140000	USD
CY2017	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-591000	USD
CY2016	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-608000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-773000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-525000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-535000	USD
CY2018	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-139568000	USD
CY2017	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-120587000	USD
CY2016	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-89270000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-142568000	USD
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36171582	shares
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30101125	shares
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11953000	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1405000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-120587000	USD
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28114784	shares
CY2017	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-120587000	USD
CY2016	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-89270000	USD
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.94
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.01
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.18
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	253252000	USD
CY2016	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	243000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-89270000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-8000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	45000	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-5000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-142576000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-120542000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-89275000	USD
CY2018	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-142568000	USD
CY2016	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	507000	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-5000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-89270000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	177071000	USD
CY2017	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	583000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13230000	USD
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	38157000	USD
CY2017	rvnc	Stock Issued During Period Value New Issues Follow On Offering StockIssuedDuringPeriodValueNewIssuesFollowOnOffering	156933000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3986000	USD
CY2017	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	573000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	45000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-120587000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	268845000	USD
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	765000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16273000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4527000	USD
CY2018	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2212000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-8000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-142568000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	145622000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-142568000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-120587000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-89270000	USD
CY2018	us-gaap	Depreciation Depreciation	1726000	USD
CY2017	us-gaap	Depreciation Depreciation	1468000	USD
CY2016	us-gaap	Depreciation Depreciation	1445000	USD
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1103000	USD
CY2017	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-410000	USD
CY2016	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1212000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	16273000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	11953000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	13230000	USD
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1466000	USD
CY2017	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2016	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2018	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2017	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2927000	USD
CY2016	us-gaap	Asset Impairment Charges AssetImpairmentCharges	9059000	USD
CY2018	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2017	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2016	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	2000000	USD
CY2018	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	175000	USD
CY2017	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	767000	USD
CY2016	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1013000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	26952000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-80000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-30000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2911000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4849000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5621000	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1871000	USD
CY2017	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	403000	USD
CY2016	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	151000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1691000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	2607000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	953000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1609000	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-565000	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	7502000	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	51272000	USD
CY2017	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2016	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2018	rvnc	Increase Decreasein Deferred Rent IncreaseDecreaseinDeferredRent	-121000	USD
CY2017	rvnc	Increase Decreasein Deferred Rent IncreaseDecreaseinDeferredRent	-125000	USD
CY2016	rvnc	Increase Decreasein Deferred Rent IncreaseDecreaseinDeferredRent	48000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-104246000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-95342000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-59827000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6991000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2525000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1670000	USD
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1541000	USD
CY2017	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2016	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000	USD
CY2017	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	100000	USD
CY2018	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	314911000	USD
CY2017	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	36028000	USD
CY2016	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	280681000	USD
CY2018	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	146000000	USD
CY2017	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	157445000	USD
CY2016	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	207650000	USD
CY2018	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	67435000	USD
CY2017	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	USD
CY2016	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	1000000	USD
CY2018	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	100000	USD
CY2016	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	1800000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-107026000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	118792000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-75499000	USD
CY2018	rvnc	Proceeds From Issuanceof Follow On Offering Netof Commissionsand Discount ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount	0	USD
CY2017	rvnc	Proceeds From Issuanceof Follow On Offering Netof Commissionsand Discount ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount	157468000	USD
CY2016	rvnc	Proceeds From Issuanceof Follow On Offering Netof Commissionsand Discount ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	38760000	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5292000	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4569000	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1649000	USD
CY2018	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	932000	USD
CY2017	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	3636000	USD
CY2016	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	3541000	USD
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2212000	USD
CY2017	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	573000	USD
CY2016	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	507000	USD
CY2018	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	366000	USD
CY2017	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	644000	USD
CY2016	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	243000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1782000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	195944000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2642000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-209490000	USD
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	219394000	USD
CY2016	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-137968000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	283476000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64082000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	16000	USD
CY2015Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	202050000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73986000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	283476000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64082000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	299000	USD
CY2016	us-gaap	Interest Paid Net InterestPaidNet	676000	USD
CY2018	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	354000	USD
CY2017	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	251000	USD
CY2016	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	134000	USD
CY2018	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	642000	USD
CY2017	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	718000	USD
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	200000	USD
CY2018	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0	USD
CY2017	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0	USD
CY2016	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	200000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-142600000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-120600000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-89300000	USD
CY2018Q4	rvnc	Working Capital Surplus WorkingCapitalSurplus	176000000.0	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-684800000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	175800000	USD
CY2018	rvnc	Cashand Cash Equivalentsand Investments Operating Plan Funding Term Minimum CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum	P12M
CY2018	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span></div>The preparation of Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. Such management estimates include revenue recognition, deferred revenue, accruals including clinical trial accruals, stock-based compensation, fair value of derivative liability, impairment of long-lived assets and the valuation of deferred tax assets. The Company bases its estimates on historical experience and also on assumptions that it believes are reasonable; however, actual results could significantly differ from those estimates.
CY2018	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Concentration of Credit Risk<div style="line-height:120%;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"/>Financial instruments that potentially subject the Company to a concentration of credit risk consist of short-term investments. Under the Company's investment policy, the Company limits its credit exposure by investing in highly liquid funds and debt obligations of the United States (“U.S.”) government and its agencies with high credit quality. The Company’s cash, cash equivalents, and short-term investments are held in the U.S. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any significant losses on its deposits of cash, cash equivalents, and short-term investments.
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	700000	USD
CY2018Q4	rvnc	Restricted Cash Minimum Balance RestrictedCashMinimumBalance	500000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	175800000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	282900000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	62900000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2000000.0	USD
CY2016Q2	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	1800000	USD
CY2017Q2	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	100000	USD
CY2018Q2	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	100000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2000000.0	USD
CY2018	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	Medicis Settlement<div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2009, the Company and Medicis Pharmaceutical Corporation (“Medicis”) entered into a license agreement granting Medicis worldwide aesthetic and dermatological rights to the Company’s investigational, injectable botulinum toxin type A product candidate. In October 2012, the Company entered into a settlement and termination agreement with Medicis. The terms of the settlement provided for the reacquisition of the rights related to all territories of DAXI and DaxibotulinumtoxinA Topical from Medicis and for consideration payable by the Company to Medicis of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, comprised of (i) an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$7.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was paid in 2012, (ii) a proceeds sharing arrangement payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$14.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> due upon specified capital raising achievements by the Company, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$6.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> was paid in 2013 and </span><span style="font-family:inherit;font-size:10pt;"><span>$7.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2014, and (iii) a product approval payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to be paid upon the achievement of regulatory approval for DAXI or DaxibotulinumtoxinA Topical by the Company. Medicis was subsequently acquired by Valeant in December 2012.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determined that the settlement provisions related to the proceeds sharing arrangement payment in (ii) above and product approval payment in (iii) above were derivative instruments that require fair value accounting as a liability and periodic fair value remeasurements until settled. </span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the product approval payment derivative was determined by estimating the timing and probability of the related approval and multiplying the payment amount by this probability percentage then applying a discount factor. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">, the fair value of the product approval payment derivative of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> was determined by updating the timing and probability estimate of the related approval and applying a discount factor assuming a term of </span><span style="font-family:inherit;font-size:10pt;"><span>2.5</span></span><span style="font-family:inherit;font-size:10pt;"> years, a risk-free rate of </span><span style="font-family:inherit;font-size:10pt;"><span>2.0%</span></span><span style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>6.5%</span></span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company determined the fair value of its liability for the product approval payment was </span><span style="font-family:inherit;font-size:10pt;"><span>$2.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was measured by assuming a term of </span><span style="font-family:inherit;font-size:10pt;"><span>1.5</span></span><span style="font-family:inherit;font-size:10pt;"> years, a risk-free rate of </span><span style="font-family:inherit;font-size:10pt;"><span>2.6%</span></span><span style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>8.0%</span></span><span style="font-family:inherit;font-size:10pt;">. The Company’s assumption for the expected term is based on an expected BLA approval in 2020. The Company did not make any payments under the product approval payment during the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and 2017.</span></div><span style="font-family:inherit;font-size:10pt;">As a result of the fair value remeasurements during the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized aggregate losses of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span>, respectively.
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	171784000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	13000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	171776000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	236744000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	236744000	USD
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	102556000	USD
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	171776000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	236744000	USD
CY2018	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	28421000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	22781000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13972000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13531000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14449000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9250000	USD
CY2016	us-gaap	Asset Impairment Charges AssetImpairmentCharges	9100000	USD
CY2017	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2900000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6743000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5763000	USD
CY2018	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2018Q4	rvnc	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	4021000	USD
CY2017Q4	rvnc	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	3189000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	2272000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	1773000	USD
CY2018Q4	rvnc	Accrued Milestone Obligations AccruedMilestoneObligations	1000000	USD
CY2017Q4	rvnc	Accrued Milestone Obligations AccruedMilestoneObligations	0	USD
CY2018Q4	rvnc	Accrued Manufacturing Costs AccruedManufacturingCosts	260000	USD
CY2017Q4	rvnc	Accrued Manufacturing Costs AccruedManufacturingCosts	488000	USD
CY2018Q4	rvnc	Accrued Capital Expenditures AccruedCapitalExpenditures	111000	USD
CY2017Q4	rvnc	Accrued Capital Expenditures AccruedCapitalExpenditures	302000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	541000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	710000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14948000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12225000	USD
CY2018Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1300000	USD
CY2017Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	900000	USD
CY2014Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P36M
CY2018Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P24M
CY2018Q2	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	19000	sqft
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	5500000	USD
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	5300000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	5826000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	6011000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	6196000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	4696000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	20173000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	42902000	USD
CY2018	rvnc	Indemnification Liability Recordedduring Period IndemnificationLiabilityRecordedduringPeriod	0	USD
CY2018Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2016	rvnc	Stock Issued During Period Shares Exerciseof Warrants StockIssuedDuringPeriodSharesExerciseofWarrants	0	shares
CY2018	rvnc	Stock Issued During Period Shares Exerciseof Warrants StockIssuedDuringPeriodSharesExerciseofWarrants	0	shares
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M17D
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	8071000	USD
CY2017	rvnc	Numberof Employees Convertedto Non Employee Consultants NumberofEmployeesConvertedtoNonEmployeeConsultants	2	employee
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16273000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13230000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11953000	USD
CY2018Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3052674	shares
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000000.0	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-139568000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-118331000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-89270000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2256000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	USD
CY2018	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-139568000	USD
CY2017	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-120587000	USD
CY2016	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-89270000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	146618000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	106338000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2191000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2591000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5173000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5400000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	12230000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	6779000	USD
CY2018Q4	rvnc	Deferred Tax Assets Fixedandintangibleassets DeferredTaxAssetsFixedandintangibleassets	3328000	USD
CY2017Q4	rvnc	Deferred Tax Assets Fixedandintangibleassets DeferredTaxAssetsFixedandintangibleassets	7221000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	169540000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	128329000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-29309000	USD
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-40999000	USD
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-30352000	USD
CY2018	rvnc	Effective Income Tax Rate Reconciliation Saleof Intellectual Property Amount EffectiveIncomeTaxRateReconciliationSaleofIntellectualPropertyAmount	-14008000	USD
CY2017	rvnc	Effective Income Tax Rate Reconciliation Saleof Intellectual Property Amount EffectiveIncomeTaxRateReconciliationSaleofIntellectualPropertyAmount	14008000	USD
CY2016	rvnc	Effective Income Tax Rate Reconciliation Saleof Intellectual Property Amount EffectiveIncomeTaxRateReconciliationSaleofIntellectualPropertyAmount	0	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	4064000	USD
CY2017	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1858000	USD
CY2016	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	544000	USD
CY2018	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	2370000	USD
CY2017	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	767000	USD
CY2016	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	0	USD
CY2018	rvnc	Effective Income Tax Reconciliation Nondeductibleand Nontaxable Items EffectiveIncomeTaxReconciliationNondeductibleandNontaxableItems	108000	USD
CY2017	rvnc	Effective Income Tax Reconciliation Nondeductibleand Nontaxable Items EffectiveIncomeTaxReconciliationNondeductibleandNontaxableItems	738000	USD
CY2016	rvnc	Effective Income Tax Reconciliation Nondeductibleand Nontaxable Items EffectiveIncomeTaxReconciliationNondeductibleandNontaxableItems	832000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	5154000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	62903000	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	42902000	USD
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-41200000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	62900000	USD
CY2018Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-35783000	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	30053000	USD
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-153000	USD
CY2017	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	224000	USD
CY2016	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	11000	USD
CY2018	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	3000000	USD
CY2017	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	0	USD
CY2016	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	0	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4200000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2600000	USD
CY2018Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1537000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	9000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	273000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1819000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	758000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2577000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	333000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1290000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4200000	USD
CY2018	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	600000	USD
CY2017	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	200000	USD
CY2016	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
CY2018Q4	us-gaap	Revenues Revenues	487000	USD
CY2018Q3	us-gaap	Revenues Revenues	2362000	USD
CY2018Q2	us-gaap	Revenues Revenues	686000	USD
CY2018Q1	us-gaap	Revenues Revenues	193000	USD
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-40616000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-32834000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-34080000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-35037000	USD
CY2018Q4	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-40616000	USD
CY2018Q3	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-32834000	USD
CY2018Q2	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-34080000	USD
CY2018Q1	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-35037000	USD
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.12
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.91
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.94
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.97
CY2017Q4	us-gaap	Revenues Revenues	37000	USD
CY2017Q3	us-gaap	Revenues Revenues	75000	USD
CY2017Q2	us-gaap	Revenues Revenues	75000	USD
CY2017Q1	us-gaap	Revenues Revenues	75000	USD
CY2017Q4	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2927000	USD
CY2017Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2017Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2017Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-40616000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-30651000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-26874000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-27156000	USD
CY2017Q4	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-40616000	USD
CY2017Q3	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-30651000	USD
CY2017Q2	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-26874000	USD
CY2017Q1	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-27156000	USD
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.12
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.01
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.90
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.94

Files In Submission

Name	View Source	Status
0001479290-19-000030-index-headers.html	Edgar Link	pending
0001479290-19-000030-index.html	Edgar Link	pending
0001479290-19-000030.txt	Edgar Link	pending
0001479290-19-000030-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pipelinesummary_image.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rvnc-20181231.xsd	Edgar Link	pending
rvnc-20181231_cal.xml	Edgar Link	unprocessable
rvnc-20181231_def.xml	Edgar Link	unprocessable
rvnc-20181231_lab.xml	Edgar Link	unprocessable
rvnc-20181231_pre.xml	Edgar Link	unprocessable
rvnc1231201810k.htm	Edgar Link	pending
rvnc1231201810kex1027.htm	Edgar Link	pending
rvnc1231201810kex1028.htm	Edgar Link	pending
rvnc1231201810kex1037.htm	Edgar Link	pending
rvnc1231201810kex1038.htm	Edgar Link	pending
rvnc1231201810kex1042.htm	Edgar Link	pending
rvnc1231201810kex1042_image.jpg	Edgar Link	pending
rvnc1231201810kex2101.htm	Edgar Link	pending
rvnc1231201810kex2301.htm	Edgar Link	pending
rvnc1231201810kex3101.htm	Edgar Link	pending
rvnc1231201810kex3102.htm	Edgar Link	pending
rvnc1231201810kex3201.htm	Edgar Link	pending
rvnc1231201810kex3202.htm	Edgar Link	pending
rvnc1231201810k_htm.xml	Edgar Link	completed
Show.js	Edgar Link	pending
stockpriceperformancegraph.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RVNC
Revance Therapeutics, Inc. Stock $rvnc

2019 Q1 Form 10-K Financial Statement

#000147929019000030 Filed on February 28, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC Revance Therapeutics, Inc. Stock $rvnc

2019 Q1 Form 10-K Financial Statement

#000147929019000030 Filed on February 28, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC
Revance Therapeutics, Inc. Stock $rvnc